NAD+ (injectable)

Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.

• Marketed to raise cellular NAD+, a coenzyme central to mitochondrial energy (ATP) production and DNA repair that declines with age.
• Promoted for energy, mental clarity, reduced brain fog, mood, and addiction/withdrawal support.
• IV/injectable routes are pitched as bypassing poor oral absorption to deliver NAD+ 'directly' to the bloodstream.
• Positioned as a longevity / 'cellular reset' intervention by wellness and anti-aging clinics.

ASSUMED mechanism: NAD+ is an essential coenzyme for mitochondrial ATP production, redox reactions, and as a substrate for DNA-repair enzymes (PARPs) and sirtuins; tissue NAD+ falls with age, so the theory is that injecting NAD+ replenishes it. The human PK data complicate this: infused NAD+ is rapidly cleared and substantially cleaved to nicotinamide and ADP-ribose extracellularly, meaning cells likely take up the breakdown products and resynthesize NAD+ internally rather than importing intact NAD+. So even if benefits occur, the proposed 'direct cellular refill' picture is largely assumed and partly contradicted by the data.

Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.

• Many users report a noticeable lift in energy, mental clarity, and reduced brain fog in the days after a session or loading series, though some say the effect fades within days to a couple of weeks (anecdotal, not proof).
• A very common refrain is that the infusion itself feels rough: chest pressure/tightness, nausea, cramping, and a racing heart if run too fast, with people emphasizing that slowing the drip way down is what makes it tolerable (anecdotal).
• In addiction-recovery communities, users often credit IV NAD+ with easing withdrawal symptoms, cravings, and mood during early sobriety, frequently as part of a broader treatment program, which confounds attribution (anecdotal).
• A skeptical contingent reports little durable benefit beyond feeling hydrated and 'pampered,' and questions whether the high per-session cost justifies effects they suspect are largely placebo (anecdotal).

1. 1961Dr. Paul O'Hollaren (Shadel Hospital, Seattle) publishes an uncontrolled case series using IV NAD+ in 100+ addiction cases; notes headache and shortness of breath at faster drip rates, the first description of rate-dependent infusion reactions.
2. 2010sIV NAD+ ('NAD therapy', 'the NAD drip') spreads through addiction-recovery and concierge wellness clinics; aggressive longevity/energy marketing despite no controlled outcome data.
3. 2019Grant et al. pilot PK study (n=11) shows infused NAD+ is cleared from plasma for the first 2 hours and largely metabolized to nicotinamide and ADP-ribose, the first hard human evidence that IV NAD+ is mostly broken down, not delivered intact.
4. 2024First randomized, placebo-controlled acute pilot (NCT06382688) directly compares IV NAD+ to IV NR: NAD+ raises blood NAD+ less, is less tolerable, slower to infuse, and shows a WBC/neutrophil rise.
5. 2025-2026Retrospective tolerability pilot and PRISMA-guided reviews reaffirm: every IV NAD+ patient had moderate-to-severe infusion symptoms, and controlled OUTCOME evidence for anti-aging/wellness remains absent.

Cross-checked across a 2019 PK pilot (PMC6751327), a 2024 randomized placebo-controlled acute pilot (NCT06382688), a 2025-2026 retrospective tolerability pilot (PMC12907335), PRISMA/systematic reviews, and regulatory/FDA compounding guidance. Findings are strikingly consistent: IV NAD+ exists and is broadly survivable but is largely degraded en route, less efficient and less tolerable than IV NR, and unsupported by any clinical-outcome RCT. Note: the strongest head-to-head dataset comes from the NR/Niagen commercial sphere, so its 'NR is superior' framing is an interested conclusion, but the underlying data on injectable NAD+ are independent of that spin.

• Grant et al. (2019). Human plasma & urine NAD+ metabolome during 6-h IV NAD+ infusion (PMC6751327) ↗· Foundational human PK pilot (n=11): infused NAD+ cleared from plasma for first 2 h and largely cleaved to nicotinamide/ADP-ribose. Best evidence that IV NAD+ is mostly degraded en route.
• Acute randomized placebo-controlled pilot: IV NR vs IV NAD+ vs oral NR vs saline (NCT06382688) ↗· Only acute RCT directly testing IV NAD+. Surrogate endpoint (blood NAD+), not clinical outcome; IV NAD+ less effective/less tolerable than NR, with a WBC/neutrophil rise. Industry-adjacent, read framing critically.
• IV NAD+ vs NR retrospective tolerability pilot, Frontiers in Aging (PMC12907335) ↗· Real-world pilot: 100% of IV NAD+ recipients had moderate-to-severe infusion symptoms; ~97 min infusions. Small, retrospective.
• PubMed. NAD+ intravenous infusion (human literature search) ↗· Scoping the field: the precise query returns only a couple of healthy-adult studies, the thinness of injectable-NAD+ outcome data is itself the headline.
• FDA / DailyMed, compounded NAD+ regulatory context ↗· Injectable NAD+ is not FDA-approved; supplied by 503A/503B compounders. FDA has warned against food-grade NAD+ for IV use (contamination/AE risk).